Ryan Halsted
Stock Analyst at RBC Capital
(3.66)
# 2,156
Out of 4,634 analysts
93
Total ratings
60%
Success rate
8.9%
Average return
Main Sectors:
Stocks Rated by Ryan Halsted
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVH Evolent Health | Maintained: Hold | $3 | $3.93 | -23.66% | 6 | Aug 6, 2026 | |
| SHC Sotera Health Company | Reiterated: Buy | $24 | $18.97 | +26.52% | 10 | Aug 6, 2026 | |
| PRVA Privia Health Group | Reiterated: Buy | $31 | $22.37 | +38.58% | 8 | Aug 6, 2026 | |
| DOCS Doximity | Reiterated: Buy | $28 | $25.63 | +9.25% | 10 | Aug 6, 2026 | |
| CRL Charles River Laboratories International | Maintained: Buy | $215 → $282 | $277.00 | +1.81% | 5 | Aug 5, 2026 | |
| MDLN Medline | Maintained: Buy | $53 → $46 | $33.81 | +36.05% | 7 | Aug 5, 2026 | |
| ICLR ICON Public Limited Company | Maintained: Buy | $185 | $166.05 | +11.41% | 5 | Jul 30, 2026 | |
| WAY Waystar Holding | Reiterated: Buy | $44 | $24.70 | +78.14% | 8 | Jul 29, 2026 | |
| IQV IQVIA Holdings | Reiterated: Buy | $221 → $247 | $241.99 | +2.07% | 6 | Jul 28, 2026 | |
| MEDP Medpace Holdings | Reiterated: Buy | $484 → $692 | $602.43 | +14.87% | 6 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $24 | $21.78 | +10.19% | 5 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $108 | $106.79 | +1.13% | 3 | Jul 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 | $12.44 | +52.73% | 5 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $13.69 | n/a | 4 | Jan 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $41.99 | n/a | 1 | Oct 6, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $83.40 | n/a | 1 | Sep 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $22 | $183.94 | n/a | 3 | May 12, 2016 |
Evolent Health
Aug 6, 2026
Maintained: Hold
Price Target: $3
Current: $3.93
Upside: -23.66%
Sotera Health Company
Aug 6, 2026
Reiterated: Buy
Price Target: $24
Current: $18.97
Upside: +26.52%
Privia Health Group
Aug 6, 2026
Reiterated: Buy
Price Target: $31
Current: $22.37
Upside: +38.58%
Doximity
Aug 6, 2026
Reiterated: Buy
Price Target: $28
Current: $25.63
Upside: +9.25%
Charles River Laboratories International
Aug 5, 2026
Maintained: Buy
Price Target: $215 → $282
Current: $277.00
Upside: +1.81%
Medline
Aug 5, 2026
Maintained: Buy
Price Target: $53 → $46
Current: $33.81
Upside: +36.05%
ICON Public Limited Company
Jul 30, 2026
Maintained: Buy
Price Target: $185
Current: $166.05
Upside: +11.41%
Waystar Holding
Jul 29, 2026
Reiterated: Buy
Price Target: $44
Current: $24.70
Upside: +78.14%
IQVIA Holdings
Jul 28, 2026
Reiterated: Buy
Price Target: $221 → $247
Current: $241.99
Upside: +2.07%
Medpace Holdings
Jul 23, 2026
Reiterated: Buy
Price Target: $484 → $692
Current: $602.43
Upside: +14.87%
Jul 22, 2026
Reiterated: Hold
Price Target: $24
Current: $21.78
Upside: +10.19%
Jul 8, 2026
Maintained: Buy
Price Target: $108
Current: $106.79
Upside: +1.13%
May 27, 2026
Maintained: Buy
Price Target: $19
Current: $12.44
Upside: +52.73%
Jan 12, 2017
Upgraded: Buy
Price Target: n/a
Current: $13.69
Upside: n/a
Oct 6, 2016
Reiterated: Hold
Price Target: n/a
Current: $41.99
Upside: n/a
Sep 9, 2016
Reiterated: Hold
Price Target: n/a
Current: $83.40
Upside: n/a
May 12, 2016
Reiterated: Hold
Price Target: $22
Current: $183.94
Upside: n/a